Lear Matapure
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Genetics top 5%
- Genetic Associations and Epidemiology
- Inflammatory Bowel Disease
Papers in
-
- COVID-19 Clinical Research Studies 11
- SARS-CoV-2 and COVID-19 Research 3
- Genetics 6
- Genetic Associations and Epidemiology 6
- Journals
- The Lancet (6 papers)Nature (4 papers)EClinicalMedicine (1 paper)Nature Communications (1 paper)Human Genetics and Genomics Advances (1 paper)
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Lear Matapure
18 papers receiving 2.7k citations
Lear Matapure's Hit Papers
Peers
Comparison fields: 5 of 98
- Infectious Diseases 1.9k
- Genetics 563
- Applied Microbiology and Biotechnology 35
- Internal Medicine 28
- Immunology 130
Countries citing papers authored by Lear Matapure
This map shows the geographic impact of Lear Matapure's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lear Matapure with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lear Matapure more than expected).
Fields of papers citing papers by Lear Matapure
This network shows the impact of papers produced by Lear Matapure. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lear Matapure. The network helps show where Lear Matapure may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 6 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 7 | 2021 | 213 | |
| 8 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 9 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 10 | 2022 | 74 | |
| 11 | 2023 | 60 | |
| 12 | 2022 | 29 | |
| 13 | 2023 | 25 | |
| 14 | 2024 | 24 | |
| 15 | 2024 | 8 | |
| 16 | 2025 | 5 | |
| 17 | 2025 | 5 | |
| 18 | 2025 | 2 | |
| 19 | 2021 | 0 |
About Lear Matapure
Lear Matapure is a scholar working on Infectious Diseases, Genetics, Pulmonary and Respiratory Medicine, Surgery and Nuclear Energy and Engineering, having authored 19 papers that have together received 2.9k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (11 papers), Genetic Associations and Epidemiology (6 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Kawasaki Disease and Coronary Complications (1 paper) and Prostate Cancer Treatment and Research (1 paper). The work is most often cited by research in Infectious Diseases (1.9k citations), Genetics (563 citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (28 citations) and Immunology (130 citations). Lear Matapure has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as The Lancet, Nature, EClinicalMedicine, Nature Communications and Human Genetics and Genomics Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.